REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO presented positive long-term follow-up data for surabgene lomparvovec in wet AMD and diabetic retinopathy at the ASRS annual meeting, demonstrating durable efficacy and safety across multiple delivery routes. In wet AMD, patients maintained stable to improved vision through five years with no drug-related intraocular inflammation observed at doses matching the pivotal trials. In diabetic retinopathy, 55% of participants achieved a greater than 2-step improvement on the DRSS scale and 70% experienced no vision-threatening events at 2.5 years.
Key figures
- Guidance
- Topline data from ATMOSPHERE and ASCENT pivotal trials expected in Q4 2026
- Dr follow up years
- 2.5
- Dose level 3 gc per eye
- 1.0×10¹²
- Wet amd follow up years
- 5
- Pivotal trial enrollment
- 1200
- Dr drss improvement percentage
- 55
- Dr no vision threatening events percentage
- 70
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.